Intramedullary (Sternal) Transfusion of Human Bone Marrow

Morrison, Maurice; Samwick, A. A.

doi:10.1001/jama.1940.02810460040010

Cited by 44 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the use of a less than optimal IB-HCT approach, clinically successful engraftment has nevertheless already been reported in humans. More than half a century ago, the first reported case of successful allogeneic BM transplantation to cure BM failure employed directinjection of donor BM into the recipient's sternum (15 Tc labeled BM cells IBinfused in a volume of approximately 1000 mL resulted in radioactivity identified immediately in the heart following injection (18). Brunstein et al (17) also reported no advantage for UCB-HCT using the IB-route in terms of achieving unit dominance compared to the IV-route in the setting of a double-UCB transplant.…”

Section: Discussionmentioning

confidence: 99%

Optimization of Intrabone Delivery of Hematopoietic Progenitor Cells in a Swine Model Using Cell Radiolabeling with [89]zirconium

Pantin

Hoyt

Aras

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

y Both senior authors contributed equally to this manuscript as part of an NIH trans-Institute collaboration.Intrabone (IB) hematopoietic cell transplantation (HCT) of umbilical cord blood in humans remains experimental and the technique has not been optimized. It is unknown whether hematopoietic progenitor cells (HPCs) injected IB are initially retained in the marrow or rapidly enter into the venous circulation before homing to the marrow. To develop an IB-injection technique that maximizes HPC marrow-retention, we tracked radiolabeled human HPCs following IB-injection into swine. We developed a method to radionuclide-label HPCs using a long-lived positron emitter 89 Zr and protamine sulfate that resulted in cellularretention of low-dose radioactivity. This approach achieved radioactivity levels sufficient for detection by positron emission tomography with both high sensitivity and spatial resolution when fused with computed tomography. We found that conditions utilized in pilot IB-HCT clinical trials conducted by others led to both rapid drainage into the central venous circulation and cellular extravasation into surrounding muscle and soft tissues. By optimizing the needle design, using continuous real-time intramarrow pressure monitoring, and by reducing the infusion-volume and infusion-rate, we overcame this limitation and achieved high retention of HPCs in the marrow. This method of IB cellular delivery is readily applicable in the clinic and could be utilized in future investigational IB-HCT trials aimed at maximizing marrow retention of HPCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimization of Intrabone Delivery of Hematopoietic Progenitor Cells in a Swine Model Using Cell Radiolabeling with [89]zirconium

Pantin

Hoyt

Aras

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…We believe that this IBM-BMT is applicable to humans, because intraosseous (IO) infusion (IBM injection) is now an established method for administering fluids, drugs, and blood to critically ill patients, particularly infants. [43][44][45][46] Indeed, Hagglund and coworkers have recently compared the effectiveness of IO infusion with that of IV infusion in human allo BMT 47 ; they have concluded that allo BMT can be safely performed by IO infusion, but the incidences of acute and chronic GVHD, transplantation-related mortality, and survival rates are similar. However, they aspirated the donor BMCs from the iliac bones and infused these BMCs into the iliac bones of the recipients.…”

Section: Discussionmentioning

confidence: 99%

Intra–bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice

Kushida

Inaba

Hisha

et al. 2001

Blood

246

309

View full text Add to dashboard Cite

Intractable autoimmune diseases in chimeric resistant MRL/lpr mice were treated by a new bone marrow transplantation (BMT) method consisting of fractionated irradiation, 5.5 Gy ؋ 2, followed by intrabone marrow (IBM) injection of whole bone marrow cells (BMCs) from allogeneic normal C57BL/6 (B6) mice (5.5 Gy ؋ 2 ؉ IBM). In MRL/lpr mice treated with this method, the number of donor-derived cells in the bone marrow, spleen, and liver rapidly increased (almost 100% donor-derived cells by 14 days after the treatment), and the number of donorderived hemopoietic progenitor cells concomitantly increased. Furthermore, donorderived stromal cells were clearly detected in the cultured bone pieces from MRL/lpr mice treated with 5.5 Gy ؋ 2 ؉ IBM. All the recipients thus treated survived more than 1 year (> 60 weeks after birth) and remained free from autoimmune diseases. Autoantibodies decreased to almost normal levels, and abnormal T cells (

show abstract

“…The earliest efforts at bone marrow transplantation in humans were described by O sgood (8) and M orrison (7) working inde pendently. The former used a human marrow suspension which was injected intravenously; the latter used fresh sternal marrow which was injected intrastcrnally.…”

Section: Discussionmentioning

confidence: 99%

A Method of Hematopoietic Transplantation in Humans Using Fetal Tissue (Liver and Spleen)

Morrison¹,

Morrison²

1958

Acta Haematol

Self Cite

View full text Add to dashboard Cite

Intramedullary (Sternal) Transfusion of Human Bone Marrow

Cited by 44 publications

References 5 publications

Optimization of Intrabone Delivery of Hematopoietic Progenitor Cells in a Swine Model Using Cell Radiolabeling with [89]zirconium

Optimization of Intrabone Delivery of Hematopoietic Progenitor Cells in a Swine Model Using Cell Radiolabeling with [89]zirconium

Intra–bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice

A Method of Hematopoietic Transplantation in Humans Using Fetal Tissue (Liver and Spleen)

Contact Info

Product

Resources

About